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REFLECTION: 
Evidence-Based Practice                                 
in the New Millenium 
NICHOLUS H. YEE, M.D., Oakwood Annapolis Hospital 
 
I discussed a case with an attending physician, who was a supporter of PSA screening for prostate cancer. She gets yearly PSAs on 
her patients, “just to be safe.” She was proud to tell me she found an early cancer, presumably thinking she saved the patient’s life. I 
didn’t say anything at the time, but I was vaguely aware that screening for prostate cancer is a controversial topic. 
The next time I had a patient in for a routine physical, I considered ordering a screening PSA based on that discussion. But before I 
ordered the test, I decided to check the evidence. I had heard about a website, www.thennt.com, at a conference session on 
overdiagnosis. The website reported on a large systematic review including nearly 390,000 patients. I learned from this report that 
there is no statistically significant mortality benefit to PSA screening. The number needed to screen to save one life was infinite. The 
number needed to have a false-positive test and undergo biopsy was five. This makes the risk of harm substantial when the risk of 
benefit is zero. 
When I walked back into his room, the patient actually asked me about prostate cancer screening. I talked to him about the 
evidence. I told him testing wouldn’t save his life and that one in five men undergo biopsy for nothing. We agreed that PSA screening 
was not something that would benefit his health. 
What surprised me about this process was how quickly I learned this information and how easy it was to find. The whole process 
took me at most two minutes. In this day and age, we have so many rapid, point-of-care resources providing us with evidence. These 
resources help the patient and clinician work together to decide what is best for each patient. 
Upon reflection, what was most important was that a couple of minutes invested in reviewing the evidence made it a) easy for me to 
talk to this patient about the harms and benefits of PSA screening, and b) easy for him to understand. 
